TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Intravenous Lidocaine on Normal Sensation and Pain in Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Adult Volunteers, age \>19 years~Exclusion Criteria:~* History of Substance Abuse~* Coronary Artery Disease (CAD): unstable~* Congestive Heart Failure (CHF): unstable~* Heart Arrhythmia: symptomatic~* Chronic Obstructive Pulmonary Disease (COPD)~* Lidocaine Allergy~* Diagnostic and Statistical Manual of Mental Disorders (Rev IV): Axis I: Common Axis I disorders include depression, anxiety disorders,bipolar disorder, ADHD, and schizophrenia. Axis II: borderline personality disorder, schizotypal personality disorder, antisocial personality disorder, and mild mental retardation.~* Presence of Contraindications for MRI~* Presence of electronically, magnetically, and mechanically activated implants~* Electronically, magnetically, and mechanically activated implants~* Ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators~* Cardiac pacemakers~* Metallic splinters in the eye~* Ferromagnetic haemostatic clips in the central nervous system (CNS)~* Claustrophobia~* Pregnancy

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lidocaine (Type: EXPERIMENTAL): Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Normal Saline Flushes at 12 vs 24 Hours Intervals for Maintaining Peripheral Intravenous Catheters Patency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 1 and 17 years~* peripheral intravenous catheter 22 G or 24 G~* need to maintain the access for at least 24 hours without infusion~Exclusion Criteria:~* need for continuous infusion therapy~* programmed therapy

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Flushing every 24 hours (Type: EXPERIMENTAL): Flushing with positive pressure with normal saline every 24 hours
- Flushing every 12 hours (Type: ACTIVE_COMPARATOR): Flushing with positive pressure with normal saline every 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cook IVC Filter Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Requires temporary or permanent IVC filter placement for the prevention of PE~Exclusion Criteria:~* Less than 18 years of age~* Known hypersensitivity or contraindication to contrast medium that cannot be adequately premedicated~* Known allergy or sensitivity to cobalt, chromium, or nickel~* Pregnant or planning to become pregnant in the next 12 months~* Patient refuses blood transfusions~* At risk of septic embolism~* Medical condition or disorder that would limit life expectancy to less than 12 months or that may cause noncompliance with the protocol or confound the data analysis~* Existing IVC filter~* Duplicate IVC~* Anatomy that would prevent safe filter placement (e.g., condition of access vessels)~* IVC diameter \> 30 mm or \< 15 mm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Günther Tulip® Vena Cava Filter (Type: EXPERIMENTAL): Günther Tulip® Vena Cava Filter
- Cook Celect® Vena Cava Filters (Type: EXPERIMENTAL): Cook Celect® Vena Cava Filters

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Clinical Investigation of Toothpaste as Compared to Toothpaste and Mouthwash in Reducing Plaque and Gingivitis: A Six-week Clinical Study in the US

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects, ages 18-70, inclusive.~2. Availability for the six-week duration of the clinical research study.~3. Good general health.~4. Minimum of 20 uncrowned permanent natural teeth (excluding third molars).~5. Initial gingivitis index of at least 1.0 as determined by the use of the Loe and Silness Gingival Index.~6. Initial plaque index of at least 1.5 as determined by the use of the Quigley and Hein Plaque Index (Turesky Modification).~7. Signed Informed Consent Form~Exclusion Criteria:~1. Presence of orthodontic bands.~2. Presence of partial removable dentures.~3. Tumor(s) of the soft or hard tissues of the oral cavity.~4. Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone).~5. Five or more carious lesions requiring immediate restorative treatment.~6. Antibiotic use any time during the one month prior to entry into the study.~7. Participation in any other clinical study or test panel within the one month prior to entry into the study.~8. Dental prophylaxis during the past two weeks prior to baseline examinations.~9. History of allergies to oral care/personal care consumer products or their ingredients.~10. On any prescription medicines that might interfere with the study outcome.~11. An existing medical condition which prohibits eating or drinking for periods up to 4 hours.~12. History of alcohol or drug abuse.~13. Pregnant or lactating subjects.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Total Toothpaste (Type: ACTIVE_COMPARATOR): Triclosan/fluoride toothpaste
- Toothpaste + Mouthwash (Type: ACTIVE_COMPARATOR): Stannous fluoride toothpaste \& cetylpyridinium chloride Mouthwash
- Control group (Type: PLACEBO_COMPARATOR): fluoride toothpaste +fluoride mouthwash

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Have given written informed consent~* Women must not be at risk to become pregnant during study participation~* Diagnosis of Rheumatoid Arthritis (RA)~* Current, regular use of Methotrexate, at a stable dose~* Other criteria to be reviewed by study doctor~Exclusion Criteria:~* Use of excluded medications(reviewed by study doctor)~* Have not failed biologic tumor necrosis factor-alpha (TNF-α) inhibitor therapy~* Have had recent or ongoing infection which, in the opinion of the study doctor put patient at an unacceptable risk for participation in the study~* Evidence of tuberculosis~* Have systemic inflammatory condition other than RA, such as juvenile RA, Crohn's disease, ulcerative colitis, psoriatic arthritis or seronegative spondyloarthropathy~* Other criteria to be reviewed by study doctor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): None
- 1 mg LY2127399 (Type: EXPERIMENTAL): None
- 3 mg LY2127399 (Type: EXPERIMENTAL): None
- 10 mg LY2127399 (Type: EXPERIMENTAL): None
- 30 mg LY2127399 (Type: EXPERIMENTAL): None
- 60 mg LY2127399 (Type: EXPERIMENTAL): None
- 120 mg LY2127399 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Painful distal diabetic neuropathy~Exclusion Criteria:~* Must have an average pain intensity of ≥ 4 on an 11-point Likert scale

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with clinically definite multiple sclerosis diagnosed according to the McDonald criteria~* EDSS 4-7~* Pyramidal FS \>= 2~Exclusion Criteria:~* History of epileptic seizures~* MS relapse or change in disease modifying treatment (DMT) within 60 days~* cancer within five years~* uncontrolled hypertension~* clinically important cardiac, hepatic, renal or pulmonary disease~* pregnancy~* breast feeding~* concomitant treatment with cimetidine, carvedilol, propranolol and metformin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Fampridine-SR (Type: EXPERIMENTAL): Initially all participants receive Fampridine-SR 10 mg BID in an open label enrichment phase lasting four weeks. Those 40% responding the most by SSST will go onto phase two. 50% of these will receive 10 mg Fampridine-SR BID for four weeks.
- Placebo (Type: PLACEBO_COMPARATOR): In the intervention phase 50% will receive placebo BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Metastatic breast cancer confirmed by biopsy~* Overexpression of the Her-2 oncogene~* Age \> 18 years~* Measurable disease~* Able to perform activities of daily living with minimal assistance~* No previous chemotherapy for metastatic disease~* One or more previous hormonal therapies for metastatic disease.~* Adequate bone marrow, liver and kidney function~* Patients with \< grade 1 peripheral neuropathy are eligible.~* Must give written informed consent prior to entering this study.~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Abnormal heart function~* Previous treatment with trastuzumab~* Brain metastases untreated~* Pre-existing symptomatic peripheral neuropathy~* Serious underlying medical conditions~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Effects of GLP-1 on Renal Hemodynamics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Normal health demonstrated by medical examination.~* Normal values for fasting plasma glucose, total cholesterol, triglyceride, HDL, LDL, creatinine, AST, ALT and electrolyte concentrations.~Exclusion Criteria:~* Immunosuppressive treatment for the previous 12 months.~* Alcohol abuse.~* Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists that, in the opinion of the investigator, may interfere with glucose metabolism.~* Use of lithium.~* Medical treatment that affects insulin secretion or cardiovascular efficacy goals.~* Liver disease (ALT\> 2 x normal value).~* Renal impairment (creatinine\> 130 µM and / or albuminuria).~* Severe claustrophobia.~* MRI incompatible foreign bodies.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- human glucagon-like peptide-1 (Type: ACTIVE_COMPARATOR): Intervention:~Drug: human glucagon-like peptide-1 Other names: GLP-1
- Placebo (Type: PLACEBO_COMPARATOR): Intervention:~Drug: Placebo (saline) Other names: Placebo for human glucagon-like peptide-1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oxycodone-naloxone in Relieving Opioid-related Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects at lest 18 years or older with pain.~* Subjects must report constipation caused or aggravated by opioids.~Exclusion Criteria:~* Females who are pregnant or lactating.~* Subjects with evidence of significant structural abnormalities of the gastrointestinal (GI) tract (e.g. bowel obstruction, strictures).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • 18 years of age or older;~  * Diagnosis of any phenotypic or genotypic variation of RP, confirmed by clinical history, fundus appearance, visual field (VF), electroretinogram (ERG) and genetic mutation analysis;~ * Having experienced various degrees of VF loss;~ * BCVA from 50 letters to 110 letters in the ETDRS chart testing (Topcon CC-100 XP, Japan);~ * Mean deviation (MD) values ranging between -33.0 and -5.0 dB with Compass visual field analysis (threshold 24-2, Sita Standard, Stimulus 3-white);~ * Intraocular pressure (IOP) of \<22 mmHg.~Exclusion Criteria:~* • The presence of cataracts or other media opacity that might affect the VF, MD, or ERG recordings;~  * The presence of glaucoma, which causes visual field and optic disc changes;~ * The presence of any systemic disorder (e.g.,diabetes, neurological disease, or uncontrolled systemic hypertension) that may affect visual function;~ * The habit of smoking.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Before application (Type: ACTIVE_COMPARATOR): RP patients with progressive visual acuity and visual field loss: before stem cell application.
- After application (Type: ACTIVE_COMPARATOR): RP patients, after stem cell applications.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically-proven diagnosis of malignant GIST not amenable to surgery, radiation or combined modality treatment with curative intent~* Failed Gleevec treatment or intolerant to Gleevec therapy~Key Exclusion Criteria:~* Treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or investigational agent since the last dose of Gleevec

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B (Type: PLACEBO_COMPARATOR): None
- A (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Morphine vs. Oxycodone for Postoperative Pain Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (American Society of Anaesthesiologists (ASA) I, II and III) due for elective, laparoscopic, non-malignant gynaecologic surgery: Hysterectomy or myomectomy.~* Written informed consent.~* Age: 18 to 70 years.~Exclusion Criteria:~* Patients having used non-steroidal anti-inflammatory drugs (NSAIDs) the last 24 hours.~* Sensitivity towards the study drugs.~* Cardiovascular risk conditions: Heart failure, unstable hypertension, coronary artery disease.~* Patients using opioids, steroids or anti-emetic drugs.~* Serious mental disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- O (Type: ACTIVE_COMPARATOR): This arm will receive intravenous oxycodone at the end of surgery and PCA oxycodone for postoperative pain relief.
- M (Type: ACTIVE_COMPARATOR): This arm will receive intravenous morphine at the end of surgery and PCA morphine for postoperative pain relief.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Anticoagulation Control in VISN 1

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients receiving long-term oral anticoagulation with warfarin within the VA New England Region (VISN 1)~Exclusion Criteria:~* Patients with valvular heart disease, who may have an INR target range other than 2-3. This usually represents between 10-15% of patients receiving anticoagulation.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): VA patients treated at anticoagulation clinics at 8 sites in VISN 1. The intervention included a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
- Control Group (Type: NO_INTERVENTION): VA patients treated at anticoagulation clinics at 116 sites outside of VISN 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent (IC) obtained.~* Histologically confirmed adenocarcinoma of prostate~* Progressive metastatic disease~* Ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone (LHRH) analogue or antagonist or bilateral orchiectomy~* Adequate bone marrow, hepatic and renal function~* Able to swallow the ODM-201 whole as a capsule or tablet.~Exclusion Criteria:~* Previous chemotherapy for prostate cancer.~* Known metastases in the brain.~* History of other malignancy within the previous 5 years, except a basal cell carcinoma of skin.~* Known gastrointestinal condition that can significantly affect the absorption of the study treatment.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ODM-201 Tablet A (Type: EXPERIMENTAL): ODM-201 tablet A in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
- ODM-201 Tablet B (Type: EXPERIMENTAL): ODM-201 Tablet B in fed and fasted states plus ODM-201 capsule in fed state in randomised order.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete